Ferndale-based Vancive Medical Technologies and Eloquest Healthcare, a subsidiary of Ferndale Pharma Group, today announced a partnership for the development of a post-operative dressing that contains the antimicrobial agent chlorhexidine gluconate (CHG), which contains antimicrobial properties inhibit microbial growth within the dressing.
CHG does not easily incorporate in an absorbent adhesive dressing, making the development of the BeneHold CHG platform a significant advancement. The Eloquest Healthcare ReliaTect Post-Op Dressings with CHG are the first to combine CHG in an absorbent, transparent, and waterproof design.
“ReliaTect post-operative dressings are a natural fit for our BeneHold CHG platform, and the needs of patients and clinicians,” says Kirsten Newquist, general manager for Vancive Medical Technologies. “We look forward to further expanding our CHG technology to many more applications.”
ReliaTect is available in small and large sizes with a transparent window for surgical site visualization. The nonwoven border allows for dressing application, making it more secure for the patient. The dressings adhere to the skin, absorb fluids, and protect the site from external contaminants.
“Chlorhexidine Gluconate (CHG) is a trusted antiseptic in pre-operative site treatment,” says Tim O’Halla, president and CEO for Eloquest Healthcare. “By combining its antimicrobial properties with the sustained transparency and absorbency of our ReliaTect Post-Op Dressings, we are bringing to market a truly patient friendly post-operative dressing with proven antimicrobial activity.”
ReliaTect Post-Op Dressings with CHG are now commercially available from Eloquest Healthcare in the U.S. The dressings received 510(k) clearance from the FDA in March and are now available throughout the nation. Eloquest Healthcare is the only distributor of the dressings in the U.S. and Canada.
For more information or to request a sample, click here.